Examples of 'linagliptin' in a sentence
Meaning of "linagliptin"
Linagliptin (noun) - A prescription medication used to treat type 2 diabetes by regulating blood sugar levels
Show more definitions
- A DPP-4 inhibitor developed for treatment of type II diabetes.
How to use "linagliptin" in a sentence
Basic
Advanced
linagliptin
Linagliptin in combination with metformin and insulin.
The active substances are linagliptin and metformin.
Linagliptin as monotherapy in patients ineligible for metformin.
Side effects when taking linagliptin alone.
Linagliptin alone showed a comparable incidence of hypoglycaemia to placebo.
The active substances are empagliflozin and linagliptin.
Effects of linagliptin on other medicinal products.
Metabolism plays a subordinate role in the elimination of linagliptin.
Linagliptin has not been studied in combination with insulin.
Adverse reactions by treatment regimen linagliptin plus metformin.
Linagliptin does not work when the blood glucose is low.
Bullous pemphigoid has been observed in patients taking linagliptin.
Linagliptin provided significant improvements in.
Acute pancreatitis has been observed in patients taking linagliptin.
These changes in linagliptin pharmacokinetics were not considered to be clinically relevant.
See also
Empagliflozin in patients inadequately controlled on metformin and linagliptin.
The use of linagliptin has not been studied in pregnant women.
Trajenta is a medicine that contains the active substance linagliptin.
It is not known whether linagliptin is excreted into human milk.
Linagliptin administered during the period of organogenesis was not teratogenic.
It is not known whether linagliptin passes into human milk.
It is a combination of empagliflozin and linagliptin.
Linagliptin and its main metabolite did not show a genotoxic potential.
The active substance is linagliptin.
Adverse reactions reported when linagliptin and metformin were combined with insulin.
No studies on the effect on human fertility have been conducted for linagliptin.
Adverse reactions by treatment regimen linagliptin plus metformin plus sulphonylurea.
When already being treated with the free combination of empagliflozin and linagliptin.
Adverse reactions by treatment regimen linagliptin plus metformin plus insulin.
Another group of mice were fed a western diet containing a low dose of linagliptin.
Adverse reactions reported when linagliptin and metformin were combined with sulphonylurea.
In vitro assessment of linagliptin.
All side effects of linagliptin alone are listed for Jentadueto.
It contains two different active substances linagliptin and metformin.
The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea.
No data in humans are available on excretion of empagliflozin and linagliptin into milk.
Studies characterising the pharmacokinetics of linagliptin in paediatric patients have not been yet performed.
Safety data from this study was in line with previous known safety profile of linagliptin.
Studies characterizing the pharmacokinetics of linagliptin in paediatric patients have not been yet performed.
Linagliptin has been authorised in the EU as Trajenta since.
Hypoglycaemia with linagliptin.
Empagliflozin and linagliptin as add-on therapy to metformin.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo.
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy.
There are no data from the use of empagliflozin and linagliptin in pregnant women.
The dose of linagliptin is 5 mg once daily.
Jentadueto is a medicine that contains the active substances linagliptin and metformin hydrochloride.
Linagliptin as add-on to metformin therapy.
In patients already being treated with the combination of linagliptin and metformin as separate tablets.
In one study linagliptin was given as add-on to metformin plus sulphonylurea.
